Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage

Table 2

The baseline physiological characteristics and laboratory results of IPPFE and IPF patients.

	IPPFE	IPF	value
	()	()
FVC %pred (%)	71.8 ± 19.4	88.2 ± 18.5	<0.01
FEV1/FVC (%)	86.0 ± 13.2	82.8 ± 7.29	<0.01
TLC %pred (%)	74.3 ± 14.2	78.3 ± 16.3	0.21
RV %pred (%)	76.9 ± 18.5	68.1 ± 19.3	0.10
RV/TLC (%)	40.2 ± 9.15	29.6 ± 6.90	<0.01
DLco %pred (%)	52.4 ± 12.9 ()	51.7 ± 14.8 ()	0.55
SpO2 (%)	96.6 ± 1.50	96.3 ± 1.58	0.42
A-aDO2 (Torr)	12.2 ± 11.1 ()	13.0 ± 7.45 ()	0.57
PaCO2 (Torr)	43.4 ± 3.57 ()	40.8 ± 3.40 ()	<0.01
ANA (<320/≥320)	24/5	61/6	0.30
SP-A (ng/ml)	61.2 ± 22.3	84.2 ± 45.1	<0.01
SP-A (<43.8/≥43.8 ng/ml)	6/23	7/60	0.15
SP-D (ng/ml)	308 ± 204	258 ± 154	0.40
SP-D (<110/≥110 ng/ml)	4/25	9/58	0.60
KL-6 (U/ml)	894 ± 565	1225 ± 701	<0.01
KL-6 (<500/≥500 U/ml)	8/21	5/62	0.01
GAP index	3.9 ± 1.8	3.6 ± 1.4	0.43

Data presented as the mean ± SD or numbers. FVC = forced vital capacity; FEV1 = forced expiratory volume in 1 s; TLC = total lung capacity; RV = residual volume; DLco = diffusing capacity of the lung for carbon monoxide; SpO₂ = arterial oxygen saturation measured by pulse oximetry; A-aDO₂ = alveolar-arterial oxygen difference; ANA = antinuclear antibody; KL-6 = Krebs von den Lungen-6; SP = surfactant protein; GAP = (gender (G), age (A), and two lung physiology variables (P) (FVC and DLco)).